Johnson & Johnson's CARVYKTI Shows 80% Progression-Free Survival in Standard-Risk Myeloma Patients
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Significant Efficacy: In the CARTITUDE-4 study, 80% of standard-risk multiple myeloma patients remained progression-free at 30 months after receiving CARVYKTI®, demonstrating the therapy's durable efficacy and treatment potential.
- Enhanced Immune Fitness: Patients treated earlier exhibited improved immune fitness, with correlational analyses suggesting that enhanced immune cell profiles are associated with longer progression-free survival (PFS), potentially shifting treatment paradigms.
- Robust Clinical Data: Over 9,000 patients globally have been treated with CARVYKTI®, and the accumulated clinical and real-world data provide a solid foundation for expanding its use, likely driving its application in earlier treatment settings.
- Broad Research Implications: The findings from the CARTITUDE-4 study offer new insights into the application of CARVYKTI® in multiple myeloma treatment, potentially enabling earlier interventions that could improve long-term remission rates.
JNJ.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 202.480
Low
176.00
Averages
207.26
High
230.00
Current: 202.480
Low
176.00
Averages
207.26
High
230.00
Guggenheim
Buy
maintain
$206 -> $227
2025-12-05
New
Reason
Guggenheim
Price Target
$206 -> $227
2025-12-05
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Johnson & Johnson to $227 from $206 and keeps a Buy rating on the shares. After reviewing the firm's J&J company model, the analyst sees "multiple drivers of additional upside" heading into 2026, the analyst tells investors.
Barclays
Equal Weight
maintain
$176 -> $197
2025-12-02
New
Reason
Barclays
Price Target
$176 -> $197
2025-12-02
New
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Johnson & Johnson to $197 from $176 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates.
Scotiabank
Outperform
initiated
$230
2025-11-12
Reason
Scotiabank
Price Target
$230
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Johnson & Johnson with an Outperform rating and $230 price target.
Freedom Capital
Ilya Zubkov
Buy
to
Hold
downgrade
$180 -> $190
2025-10-22
Reason
Freedom Capital
Ilya Zubkov
Price Target
$180 -> $190
2025-10-22
downgrade
Buy
to
Hold
Reason
Freedom Capital analyst Ilya Zubkov downgraded Johnson & Johnson to Hold from Buy with a price target of $190, up from $180. While stating that J&J "once again" exceeded both the firm's expectations and market consensus with its "robust" Q3 results and noting that the company raised its revenue guidance for the third time this year, the firm is downgrading shares as the stock is now trading near its fair value estimate.
See All Ratings
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contribute to significant inflows in ETFs like XLV and JNJ?
How does insider buying activity signal confidence in Johnson & Johnson's future?
Will Johnson & Johnson's stock continue to grow after spinning off its consumer division?
Can the approval of nipocalimab improve Johnson & Johnson's market position in Europe?